Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, O'Brien M, Rao S, Hotta K, Leiby MA, Lubiniecki GM, Shentu Y, Rangwala R, Brahmer JR, KEYNOTE-024 Investigators

Open source

DOI: 10.1056/nejmoa1606774
Published: 2016 Nov 10
Container: The New England journal of medicine
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa1606774,
  title = {Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.},
  author = {Reck M and Rodríguez-Abreu D and Robinson AG and Hui R and Csőszi T and Fülöp A and Gottfried M and Peled N and Tafreshi A and Cuffe S and O'Brien M and Rao S and Hotta K and Leiby MA and Lubiniecki GM and Shentu Y and Rangwala R and Brahmer JR and KEYNOTE-024 Investigators},
  year = {2016},
  journal = {The New England journal of medicine},
  doi = {10.1056/nejmoa1606774},
  url = {https://doi.org/10.1056/nejmoa1606774}
}

RIS

TY  - JOUR
TI  - Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
AU  - Reck M
AU  - Rodríguez-Abreu D
AU  - Robinson AG
AU  - Hui R
AU  - Csőszi T
AU  - Fülöp A
AU  - Gottfried M
AU  - Peled N
AU  - Tafreshi A
AU  - Cuffe S
AU  - O'Brien M
AU  - Rao S
AU  - Hotta K
AU  - Leiby MA
AU  - Lubiniecki GM
AU  - Shentu Y
AU  - Rangwala R
AU  - Brahmer JR
AU  - KEYNOTE-024 Investigators
PY  - 2016
JO  - The New England journal of medicine
DO  - 10.1056/nejmoa1606774
UR  - https://doi.org/10.1056/nejmoa1606774
ER  -

APA

M, R., D, R., AG, R., R, H., T, C., A, F., M, G., N, P., A, T., S, C., M, O., S, R., K, H., MA, L., GM, L., Y, S., R, R., JR, B., & Investigators, K. (2016). Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.. The New England journal of medicine. https://doi.org/10.1056/nejmoa1606774

Source records

pubmed · retrieved 2026-11-10T07:57:52.951Z